Van Strydonck, Gerald E. 4
4 · VACCINEX, INC. · Filed May 18, 2020
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Van Strydonck, Gerald E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-05-14+15,679→ 15,679 totalExercise: $3.95From: 2021-05-14→ Common Stock (15,679 underlying)
Holdings
- 2,385
Stock Option (Right to Buy)
Exercise: $5.52From: 2019-06-30Exp: 2029-06-29→ Common Stock (2,385 underlying) - 7,500
Stock Option (Right to Buy)
Exercise: $14.90Exp: 2023-03-06→ Common Stock (7,500 underlying) - 6,396
Stock Option (Right to Buy)
Exercise: $13.60Exp: 2027-09-15→ Common Stock (6,396 underlying) - 2,501
Stock Option (Right to Buy)
Exercise: $5.26Exp: 2029-03-30→ Common Stock (2,501 underlying) - 7,718
Stock Option (Right to Buy)
Exercise: $7.78From: 2020-05-15→ Common Stock (7,718 underlying) - 1,856
Stock Option (Right to Buy)
Exercise: $7.17From: 2019-09-30Exp: 2029-09-27→ Common Stock (1,856 underlying) - 2,737
Stock Option (Right to Buy)
Exercise: $4.85From: 2019-12-31Exp: 2029-12-28→ Common Stock (2,737 underlying)
Footnotes (3)
- [F1]Exercisable in full as of the date of this report.
- [F2]This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F3]This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.